Allergan AGN
The three reasons
- 1
Valeant's Outsider-CEO model delivered 2,544% TSR (25x) in six years under Mike Pearson
- 2
74% of Val-gan's sales are durable and deserve 19x-29x P/E like Perrigo, Zoetis, and global beauty peers
- 3
Large margin of safety: Val-gan only needs 7.4x 2014 cash EPS to match Allergan's unaffected price
Primary demands
- Allergan shareholders should support Valeant's proposed merger (cash + 0.83 Valeant shares per Allergan share)
- Allergan board should engage with Valeant on the business combination
- Recognize and credit Valeant's 'Platform Value' and Outsider-CEO capital allocation model
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (8)
Notes
Filed as SEC Rule 425 proxy material supporting Valeant's hostile bid for Allergan. Unusual posture: Pershing is the largest Allergan shareholder but is co-bidding WITH the acquirer (Valeant) rather than running a standalone activist campaign against Allergan management. Deck primarily defends Valeant's business model, non-GAAP 'Cash Net Income' accounting, and 'Platform Value' concept (borrowing The Outsiders/Thorndike framing) to justify why Allergan shareholders should accept Valeant stock. No direct attack on Allergan CEO/board by name — tone stays analytical and educational rather than adversarial. Target 'villain' is implicit traditional-pharma R&D orthodoxy rather than a named person. Campaign ultimately failed: Allergan was acquired by Actavis in Nov-2014, not Valeant. Pershing Square + Valeant later settled insider-trading lawsuits related to this accumulation program (~$290mm in 2017-2018). Clean institutional slide production — blue-and-green palette, Pershing-diamond logo, readable but not Ackman-CP tier; many pages are text-heavy bullets.